PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, Sandip Pravin, Kurzrock, Razelle·2015·Molecular Cancer Therapeutics
DOI 10.1158/1535-7163.mct-14-0983

Cited by (1,001)

Items 101–200 of 1,001

  1. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
    Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei · 2018 · Trends in Biochemical Sciences
  2. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
    Barbara Ann Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro Jr, Amanda K. Psyrri, Irene Braña, Neus Basté, Prakash Neupane et al. · 2022 · Journal of Clinical Oncology
  3. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
    Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark et al. · 2021 · Frontiers in Oncology
  4. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
    2017
  5. TMB or not TMB as a biomarker: That is the question
    Alfredo Addeo, Alex Friedlaender, Giuseppe Luigi Banna, Glen J. Weiss · 2021 · Critical Reviews in Oncology/Hematology
  6. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
    Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L. · 2018 · Journal for ImmunoTherapy of Cancer
  7. Cancer Neoantigens and Applications for Immunotherapy
    Alexis Desrichard, Alexandra Snyder, Timothy An-thy Chan · 2015 · Clinical Cancer Research
  8. Checkpoint inhibitors in pancreatic cancer
    Andreas Henriksen, Anne Dyhl-Polk, Inna Markovna Chen, Dorte Lisbet Nielsen · 2019 · Cancer Treatment Reviews
  9. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
    Brandon W. Higgs, Christopher A. Morehouse, Katie L. Streicher, Philip Z. Brohawn, Fernanda Pilataxi, Ashok Kumar Gupta, Koustubh Ranade · 2018 · Clinical Cancer Research
  10. Cancer immunotherapy: it’s time to better predict patients’ response
    Charlotte Pilard, Marie Ancion, Philippe Delvenne, Guy Jérusalem, Pascale Hubert, Michael F. Herfs · 2021 · British Journal of Cancer
  11. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases
    Emanuela F. T. Veras, Robert J. Kurman, Tian‐Li Wang, Ie‐Ming Shih · 2016 · International Journal of Gynecological Pathology
  12. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
    Shirish M. Gadgeel, Nathan A. Pennell, Mary J. Fidler, Balázs Halmos, Philip Bonomi, James P. Stevenson, Bryan James Schneider, Ammar W. Sukari, Jaclyn Ventimiglia, Wei Chen et al. · 2018 · Journal of Thoracic Oncology
  13. Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
    Tuuli Ranki, Sari Anneli Pesonen, Akseli Hemminki, Kaarina P. L. Partanen, Kalevi Kairemo, Tuomo Alanko, Johan E. Lundin, Nina Linder, Riku Turkki, Ari P. Ristimaki et al. · 2016 · Journal for ImmunoTherapy of Cancer
  14. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
    Yulian Khagi, Aaron Michael Goodman, Gregory A. Daniels, Sandip Pravin Patel, Assuntina Gesualda Sacco, James Michael Randall, Lyudmila A. Bazhenova, Razelle Kurzrock · 2017 · Clinical Cancer Research
  15. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
    Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
  16. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
    Esra A. Akbay, Shohei Koyama, Yan Liu, Ruben Dries, Lauren E. Bufe, Michael Silkes, Md Maksudul Alam, Dillon M. Magee, Robert E. Jones, Masahisa Jinushi et al. · 2017 · Journal of Thoracic Oncology
  17. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
    Shuang George Zhao, Jonathan M. Lehrer, Sei‐Won Laura Chang, Rajdeep Das, Nicholas Erho, Yang Liu, Martin Sjöström, Robert Benjamin Den, Stephen J. Freedland, Eric A. Klein et al. · 2018 · JNCI Journal of the National Cancer Institute
  18. SMARCA4 : Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
    Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, Shumei Kato, Razelle Kurzrock · 2021 · Molecular Cancer Therapeutics
  19. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
    Subrata Chowdhury, Joe Veyhl, Fatima Jessa, Olena Polyakova, Ahmed Alenzi, Christina MacMillan, Ranju Ralhan, Paul G. Walfish · 2016 · Oncotarget
  20. Synthesis and Biologic Evaluation of a Novel 18 F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
    David J. Donnelly, R. Adam Smith, Paul E. Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin C. Wright et al. · 2017 · Journal of Nuclear Medicine
  21. The Role of the Estrogen Pathway in the Tumor Microenvironment
    Natalie J. Rothenberger, Ashwin Somasundaram, Laura P. Stabile · 2018 · International Journal of Molecular Sciences
  22. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
    David M. O’Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Wenge Wang et al. · 2021 · Journal of Clinical Oncology
  23. Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment
    Shaobo Ruan, Rou Xie, Lin Qin, Meinan Yu, Wei Xiao, Chuan Hu, Wenqi Yu, Zhiyong Qian, Liang Ouyang, Qin He et al. · 2019 · Nano Letters
  24. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
    Emeka K. Enwere, Elizabeth N. Kornaga, Michelle Liane Dean, Theodora A. Koulis, Tien Phan, Maria Kalantarian, Martin Köbel, Prafull Ghatage, Anthony M. Magliocco, Susan P. Lees‐Miller et al. · 2017 · Modern Pathology
  25. Current state of immunotherapy for non-small cell lung cancer
    Jyoti Dhar Malhotra, Salma K. Jabbour, Joseph Aisner · 2007 · Translational Lung Cancer Research
  26. Correlate tumor mutation burden with immune signatures in human cancers
    Xiaosheng Wang, Mengyuan Li · 2019 · BMC Immunology
  27. Targeting ARID1A mutations in cancer
    Mullen, Jaren, Kato, Shumei, Sicklick, Jason K., Kurzrock, Razelle · 2021 · Cancer Treatment Reviews
  28. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
    Jin Sheng, Wenfeng Fang, Juan Yu, Nan Chen, Jianhua Zhan, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Li Zhang · 2016 · Scientific Reports
  29. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
    Yunlong Zhao, Devin L. Harrison, Yuran Song, Jie Ji, Jun Huang, Enfu Hui · 2018 · Cell Reports
  30. Nanobody: a promising toolkit for molecular imaging and disease therapy
    Guangfa Bao, Ming Tang, Jun Zhao, Xiaohua Zhu · 2021 · EJNMMI Research
  31. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
    Kazuki Takada, Tatsuro Okamoto, Fumihiro Shoji, Mototsugu Shimokawa, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Yuzo Suzuki, Takatoshi Fujishita, Gouji Toyokawa et al. · 2016 · Journal of Thoracic Oncology
  32. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer
    Mingyi Ju, Jia Bi, Qian Wei, Longyang Jiang, Qiutong Guan, Ming Zhang, Xinyue Song, Ting Chen, Jingyi Fan, Xiaojuan Li et al. · 2020 · Briefings in Bioinformatics
  33. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
    Saby George, Robert John Motzer, Hans J. Hammers, Bruce G. Redman, Timothy Michael Kuzel, Scott S. Tykodi, Elizabeth R. Plimack, Joel Jiang, Ian M. Waxman, Brian I. Rini · 2016 · JAMA Oncology
  34. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
    Delphine Daydé, Ichidai Tanaka, Rekha Jain, Mei-Chee Tai, Ayumu Taguchi · 2017 · International Journal of Molecular Sciences
  35. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
    Ruf, Melanie, Moch, Holger, Schraml, Peter · 2016 · International Journal of Cancer
  36. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
    Michael J Wagner, Megan K. D. Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, George Thomas Budd, Adrienne I. Victor, Chung-Tsen Hsueh, Rashmi K Chugh et al. · 2021 · Journal for ImmunoTherapy of Cancer
  37. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
    Dan Zhu, Ruidan Xu, Xinping Huang, Zefang Tang, Yonglu Tian, Jinfang Zhang, Xiaofeng Zheng · 2020 · Cell Death and Differentiation
  38. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
    Xin Chen, Xiaomin Song, Kang Li, Tong Zhang · 2019 · Frontiers in Immunology
  39. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter, Mark A. Socinski, Liza Cosca Villaruz · 2017 · Molecular Diagnosis & Therapy
  40. Comprehensive screening for PD-L1 expression in thyroid cancer
    Soomin Ahn, Tae Hyuk Kim, Sun Wook Kim, Chang‐Seok Ki, Hye Won Jang, Jee Soo Kim, Hyun Jung Kim, Jun‐Ho Choe, Jung Hee Shin, Soo Yeon Hahn et al. · 2017 · Endocrine Related Cancer
  41. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Laurence P. Diggs, Eddy C. Hsueh · 2017 · Biomarker Research
  42. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
    Lili Mao, Zhonghui Qi, Li Zhang, Jun Guo, Lu Si · 2021 · Frontiers in Immunology
  43. Inhibitors of the PD-1 Pathway in Tumor Therapy
    Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
  44. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
    Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jong Seok Lee · 2017 · Cancer Immunology Immunotherapy
  45. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
    Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang · 2019 · EBioMedicine
  46. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
    John de Groot, Marta Peñas-Prado, Kristin D. Alfaro-Munoz, Kathy Hunter, Be Lian Pei, Barbara Jane O'Brien, Shiao-Pei S. Weathers, Monica Elena Loghin, Carlos Kamiya Matsouka, W.K. Alfred Yung et al. · 2019 · Neuro-Oncology
  47. Genomic landscape of DNA repair genes in cancer
    Young Kwang Chae, Jonathan Forrest Anker, Benedito A. Carneiro, Sunandana Chandra, Jason Benjamin Kaplan, Aparna Kalyan, Cesar Augusto Santa-Maria, Leonidas C. Platanias, Francis Joseph Giles · 2016 · Oncotarget
  48. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
    Apostolia Maria Tsimberidou, David S. Hong, Yang Ye, Carrie Cartwright, Jennifer J. Wheler, Gerald Steven Falchook, Aung Naing, Siqing Fu, Sarina Anne Piha-Paul, Filip Jankú et al. · 2017 · JCO Precision Oncology
  49. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
    Naoya Maekawa, Satoru Konnai, Satoshi Takagi, Yumiko Kagawa, Tomohiro Okagawa, Asami Nishimori, Ryoyo Ikebuchi, Yusuke Izumi, Tatsuya Deguchi, Chie Nakajima et al. · 2017 · Scientific Reports
  50. Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
    Christina M. Maher, Jeffrey D. Thomas, Derick A. Haas, Charles G. Longen, Halley M. Oyer, Jane Y. Tong, Felix J. Kim · 2017 · Molecular Cancer Research
  51. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
    Felicity Newell, Inês Pires da Silva, Peter A. Johansson, Alexander Maxwell Menzies, James S. Wilmott, Venkateswar Addala, Matteo Salvatore Carlino, Helen Rizos, Kátia Nones, Jarem J. Edwards et al. · 2021 · Cancer Cell
  52. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
    Anders Josefsson, Jessie R. Nedrow, Sunju Park, Sangeeta Ray Banerjee, Andrew J. Rittenbach, Fabien Jammes, Benjamin M. W. Tsui, George Sgouros · 2015 · Cancer Research
  53. CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
    Melanie Straub, Enken Drecoll, Nicole Pfarr, Wilko Weichert, Rupert Langer, Alexander Hapfelmeier, Carolin Götz, Klaus‐Dietrich Wolff, Andreas Kolk, Katja Specht · 2016 · Oncotarget
  54. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
    Crispin T. Hiley, John P. C. Le Quesne, George Santis, Rowena Sharpe, David González de Castro, Gary Middleton, Charles Swanton · 2016 · The Lancet
  55. Advances in immunotherapy for melanoma
    Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
  56. Harnessing non-destructive 3D pathology
    Jonathan T.C. Liu, Adam K. Glaser, Kaustav Bera, Lawrence D. True, Nicholas P. Reder, Kevin W. Eliceiri, Anant Madabhushi · 2021 · Nature Biomedical Engineering
  57. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
    Andreas Heindl, Ivana Šestak, Kalnisha Naidoo, Jack M. Cuzick, Mitch Dowsett, Yinyin Yuan · 2017 · JNCI Journal of the National Cancer Institute
  58. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
    Chunyan Yue, Yubo Jiang, Ping Li, Yuehua Wang, Jian Xue, Nannan Li, Da Li, Ruina Wang, Yongjun Dang, Zhiyuan Hu et al. · 2018 · OncoImmunology
  59. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
    Lanlan Gao, Qianqian Guo, Xiaoman Li, Xuan Yang, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Tao Xi et al. · 2019 · EBioMedicine
  60. Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
    Katsiaryna Marhelava, Zofia Pilch, Małgorzata Bajor, Agnieszka Graczyk‐Jarzynka, Radosław Zagożdżon · 2019 · Cancers
  61. Inhibitory receptors as targets for cancer immunotherapy
    Meghan E. Turnis, Lawrence Peter Andrews, Dario A.A. Vignali · 2015 · European Journal of Immunology
  62. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang, Adebayo Ogunniyi, Meagan Spencer Barbee, Alexander Edward Dela Cruz Drilon · 2015 · Expert Review of Anticancer Therapy
  63. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
    Kellsye P. Fabian, Michelle R. Padget, Renee Nicole Donahue, Kristen Solocinski, Yvette L. Robbins, Clint Tanner Allen, John H. Lee, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom et al. · 2020 · Journal for ImmunoTherapy of Cancer
  64. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
    Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen et al. · 2022 · Journal of Clinical Oncology
  65. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
    Sabrina A. Hogan, Anaïs Courtier, Phil Fang Cheng, Nicoletta F. Jaberg-Bentele, Simone M. Goldinger, Manuarii Manuel, Solène Perez, Nadia Plantier, Jean-François Mouret, Thi Dan Linh Nguyen‐Kim et al. · 2018 · Cancer Immunology Research
  66. PD-L1 status in breast cancer: Current view and perspectives
    Semir Vranić, Farhan Sachal Cyprian, Zoran Gatalica, Juan Palazzo · 2019 · Seminars in Cancer Biology
  67. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
  68. PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
    Wojciech G. Lesniak, Samit Chatterjee, Matthew Gabrielson, Ala Lisok, Bryan L. Wharram, Martin G. Pomper, Sridhar Nimmagadda · 2016 · Bioconjugate Chemistry
  69. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
    Jin Sun Lee, Susan Elaine Yost, Yuan Yuan · 2020 · Cancers
  70. Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study
    Janice M. Mehnert, Emily K. Bergsland, Bert H. O’Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick Alexander Ott, Michael Jon Pishvaian, Igor J. Puzanov et al. · 2020 · Cancer
  71. Engineering nanoparticle strategies for effective cancer immunotherapy
    Hong Yeol Yoon, Subramanian Tamil Selvan, Yoosoo Yang, Min Ju Kim, Dong Kee Yi, Ick Chan Kwon, Kwangmeyung Kim · 2018 · Biomaterials
  72. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
    Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kyum Kim, Sumanta Kumar Pal, Daniel J. George, Tian Zhang · 2018 · Journal for ImmunoTherapy of Cancer
  73. Cancer type-dependent correlations between TP53 mutations and antitumor immunity
    Lin Li, Mengyuan Li, Xiaosheng Wang · 2020 · DNA repair
  74. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
    Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia‐Chi Lin, Chia-Jui Yen, Yee Chao, Bhumsuk Keam, Michael B. Jameson, Ming‐Mo Hou, Yoon‐Koo Kang et al. · 2020 · Journal for ImmunoTherapy of Cancer
  75. Clinical and biological significance of circulating tumor cells in cancer
    Takaaki Masuda, Naoki Hayashi, Tomohiro Iguchi, Shuhei Ito, Hidetoshi Eguchi, Koshi Mimori · 2016 · Molecular Oncology
  76. Biomarkers for Immunotherapy: Current Developments and Challenges
    Kristen Renee Spencer, Jianfeng Wang, Ann Willman Silk, Shridar Ganesan, Howard L. Kaufman, Janice M. Mehnert · 2016 · American Society of Clinical Oncology Educational Book
  77. Predictive biomarkers of colon cancer immunotherapy: Present and future
    Wanting Hou, Yi Cheng, Hong Zhu · 2022 · Frontiers in Immunology
  78. Dissecting the biological heterogeneity of HER2-positive breast cancer
    Francesco Schettini, Aleix Prat · 2021 · The Breast
  79. Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
    Lothar C. Dieterich, Kristian Ikenberg, Timur Cetintas, Kübra Kapaklikaya, Cornelia Hutmacher, Michael J. Detmar · 2017 · Frontiers in Immunology
  80. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma
    Ting Yan, Heyang Cui, Yong Zhou, Bin Juan Yang, Pengzhou Kong, Yingchun Zhang, Yiqian Liu, Bin Wang, Yikun Cheng, Jiayi Li et al. · 2019 · Nature Communications
  81. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
    Christo Kole, Nikolaos Charalampakis, Sergios A. Tsakatikas, Michail G. Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitriοs Schizas · 2020 · Cancers
  82. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
    Ilke Tunali, Jhanelle E. Gray, Jin Qi, Mahmoud A. Abdalah, Daniel K. Jeong, Albert Güveniş, Robert J. Gillies, Matthew B. Schabath · 2019 · Lung Cancer
  83. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma
    Chuanjie Zhang, Zongtai Li, Feng Qi, Xin Hu, Jun Luo · 2019 · Annals of Translational Medicine
  84. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
    Wendy A. Cooper, Prudence Anne Russell, Maya Cherian, Edwina Duhig, David Godbolt, Peter J. Jessup, Christine Khoo, Connull Leslie, Annabelle M. Mahar, David F. C. Moffat et al. · 2017 · Clinical Cancer Research
  85. PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
    Yang Wang, Tae Hyun Kim, Shamileh Fouladdel, Zhuo Zhang, Payal Soni, Angel Qin, Lili Zhao, Ebrahim Azizi, Theodore Steven Lawrence, Nithya Ramnath et al. · 2019 · Scientific Reports
  86. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
    Stephen James Luen, Peter Stephen Savas, Stephen B. Fox, Roberto Salgado, Sherene Loi · 2017 · Pathology
  87. Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
    Kiwamu Akagi, Eiji Oki, Hiroya Taniguchi, Kaname Nakatani, Daisuke Aoki, Takeshi Kuwata, Takayuki Yoshino · 2021 · Cancer Science
  88. The potential of tumor-derived exosomes for noninvasive cancer monitoring
    Theresa L. Whiteside · 2015 · Expert Review of Molecular Diagnostics
  89. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
    Alona Zer, Mike R. Sung, Preet Walia, Leila Khoja, Manjula D. Maganti, Catherine Labbé, Frances A. Shepherd, Penelope A. Bradbury, Ronald D. Feld, Geoffrey Liu et al. · 2018 · Clinical Lung Cancer
  90. Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
    Haoyu Lyu, Mengyuan Li, Zehang Jiang, Zhixian Liu, Xiaosheng Wang · 2019 · Computational and Structural Biotechnology Journal
  91. Mechanisms of Resistance to Immune Checkpoint Blockade
    David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
  92. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy
    Dongli Cai, Jiaming Li, Dingfeng Liu, Shanjuan Hong, Qin Qiao, Qinli Sun, Pingping Li, Nanan Lyu, Tiantian Sun, Shan Xie et al. · 2019 · Cellular and Molecular Immunology
  93. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
    Raquel Salvador Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel Borràs, Jannes Govaerts, Stefan Naulaerts, Zwi Nisan Berneman, Benoit Beuselinck, Kalijn F. Bol, Jannie G. Borst et al. · 2022 · OncoImmunology
  94. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
    Xiufeng Liu, Shukui Qin · 2019 · The Oncologist
  95. PD‑L1 expression levels on tumor cells affect their immunosuppressive activity
    Zheng Yang, You‐Chen Fang, Jing Li · 2019 · Oncology Letters
  96. Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images
    Sha, Lingdao, Osinski, Boleslaw L., Ho, Irvin Y., Tan, Timothy L., Willis, Caleb, Weiss, Hannah, Beaubier, Nike, Mahon, Brett M., Taxter, Tim J., Yip, Stephen S. F · 2019 · Journal of Pathology Informatics
  97. Imaging PD-L1 Expression with ImmunoPET
    Charles Truillet, Hsueh Ling Janice Oh, Siok Ping Yeo, Chia‐Yin Lee, Loc T. Huynh, Junnian Wei, Matthew F.L. Parker, Collin Michael Blakely, Natalia Sevillano, Yung-Hua Wang et al. · 2017 · Bioconjugate Chemistry
  98. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
    Yang, Haitang, Liang, Shun-Qing, Schmid, Ralph A., Peng, Ren-Wang · 2019 · Frontiers in Oncology
  99. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Sadakatsu Ikeda, Aaron Michael Goodman, Philip R. Cohen, Taylor J. Jensen, Christopher K. Ellison, Garrett Michael Frampton, Vincent A. Miller, Sandip Pravin Patel, Razelle Kurzrock · 2016 · npj Genomic Medicine
  100. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
    Shumei Kato, Ryosuke Okamura, Joel Micah Baumgartner, Hitendra Patel, Lawrence Leichman, Kaitlyn Jane Kelly, Jason Keith Sicklick, Paul Timothy Fanta, Scott Michael Lippman, Razelle Kurzrock · 2018 · Clinical Cancer Research